Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma Clinical Trial

Official title:
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status Completed

Clinical Trial Summary

The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety and tolerability of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL by dose escalating lenalidomide

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical Trial Details

NCT number	NCT04436107
Study type	Interventional
Source	BeiGene
Contact
Status	Completed
Phase	Phase 1
Start date	September 11, 2020
Completion date	March 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04442022` - A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 2/Phase 3
Terminated	`NCT05354362` - A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 1
Completed	`NCT03886831` - A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies	Phase 1
Recruiting	`NCT05664217` - NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma	Phase 2/Phase 3
Recruiting	`NCT06164327` - Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Phase 1